GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Hicin Pharmaceutical Co Ltd (SZSE:300584) » Definitions » EV-to-Revenue

Nanjing Hicin Pharmaceutical Co (SZSE:300584) EV-to-Revenue : 4.35 (As of Jun. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing Hicin Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nanjing Hicin Pharmaceutical Co's enterprise value is ¥2,195.9 Mil. Nanjing Hicin Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥505.2 Mil. Therefore, Nanjing Hicin Pharmaceutical Co's EV-to-Revenue for today is 4.35.

The historical rank and industry rank for Nanjing Hicin Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SZSE:300584' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.08   Med: 5.1   Max: 16.09
Current: 4.35

During the past 12 years, the highest EV-to-Revenue of Nanjing Hicin Pharmaceutical Co was 16.09. The lowest was 3.08. And the median was 5.10.

SZSE:300584's EV-to-Revenue is ranked worse than
73.9% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.26 vs SZSE:300584: 4.35

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Nanjing Hicin Pharmaceutical Co's stock price is ¥15.81. Nanjing Hicin Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥4.21. Therefore, Nanjing Hicin Pharmaceutical Co's PS Ratio for today is 3.76.


Nanjing Hicin Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Nanjing Hicin Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Hicin Pharmaceutical Co EV-to-Revenue Chart

Nanjing Hicin Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.63 3.57 4.26 7.50 5.83

Nanjing Hicin Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.24 5.38 5.56 5.83 4.72

Competitive Comparison of Nanjing Hicin Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Hicin Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Hicin Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing Hicin Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nanjing Hicin Pharmaceutical Co's EV-to-Revenue falls into.



Nanjing Hicin Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nanjing Hicin Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2195.880/505.194
=4.35

Nanjing Hicin Pharmaceutical Co's current Enterprise Value is ¥2,195.9 Mil.
Nanjing Hicin Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥505.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanjing Hicin Pharmaceutical Co  (SZSE:300584) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nanjing Hicin Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.81/4.209
=3.76

Nanjing Hicin Pharmaceutical Co's share price for today is ¥15.81.
Nanjing Hicin Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.21.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanjing Hicin Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nanjing Hicin Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing Hicin Pharmaceutical Co (SZSE:300584) Business Description

Traded in Other Exchanges
N/A
Address
Heng Road 1, Nanjing Economic and Technological Development Zone, Jiangsu Province, Nanjing, CHN, 210009
Nanjing Hicin Pharmaceutical Co Ltd is a China-based company engaged in producing pharmaceutical preparations. In addition, it is also involved in manufacturing synthetic chemicals, conducting new drug research and development as well as technical transferring. The company produces series of the medicines such as antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for the cardio-cerebral system and immuno-modulate agents. The active pharmaceutical ingredients, omeprazole sodium for injection, cefepime hydrochloride for Injection and lansoprazole tablets are exported by the firm into South-Asian countries, South-American countries and European countries.
Executives
Cao Yu Ping Directors, executives
Yan Mei Qiang Directors, executives
Jiang Xiang Ming Executives
Gu Hai Independent director

Nanjing Hicin Pharmaceutical Co (SZSE:300584) Headlines

No Headlines